前收市價 | 147.20 |
開市 | 135.65 |
買盤 | 180.60 |
賣出價 | 188.90 |
拍板 | 840.00 |
到期日 | 2024-06-21 |
今日波幅 | 127.50 - 147.20 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 67 |
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.